Early trials of Russian COVID-19 vaccine show safety, immune responseToday The Lancet published the results of two nonrandomized trials (called Sputnik V) of a Russian COVID-19 vaccine candidate, which showed no serious adverse events and demonstrated that the vaccine elicited an antibody response in study participants within 21 days of administration.
The phase 1/2 trials were conducted in 76 healthy adults.The two phase 1/2 trials included a frozen formulation of the vaccine, and another involving a lyophilized (freeze-dried) formulation of the vaccine.
Both vaccines are based on two adenovirus vectors, modified with the SARS-CoV2 spike protein. In both formulations, participants received two doses of the vaccine, at day 0 and day 21.